Crossmark

Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Crossref DOI link: https://doi.org/10.1186/s40425-019-0710-1

Published Online: 2019-08-23

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mahadevan, Daruka https://orcid.org/0000-0002-2991-0361
Lanasa, Mark C.

Farber, Charles

Pandey, Manjari

Whelden, Maria

Faas, Susan J.

Ulery, Terrie

Kukreja, Anjli

Li, Lan

Bedrosian, Camille L.

Zhang, Xiaoping

Heffner, Leonard T.
License Information

Text and Data Mining valid from 2019-08-23
More Information

Article History

Received: 20 May 2019

Accepted: 14 August 2019

First Online: 23 August 2019

Ethics approval and consent to participate

: All sites consented patients per site IRB and WIRB.

: All authors read the manuscript and agree to publication.

: Academic authors have nothing to disclose. MW, SJF, TU, AK, LL, CLB, and XP are employed by Alexion Pharmaceuticals, Inc.